Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Carbohydr Polym ; 250: 116869, 2020 Dec 15.
Article in English | MEDLINE | ID: mdl-33049818

ABSTRACT

Melanoma is the most lethal form of skin cancer, with a worldwide increase in incidence. Despite the increased overall survival of metastatic melanoma patients given recent advances in targeted and immunotherapy, it still has a poor prognosis and available treatment options carry diverse severe side effects. Polysaccharides from seaweed have been shown to exert antitumor activities. Here we show in vitro and in vivo antitumor activities of a sulfated homogalactan (named 3G4S) from Codium isthmocladum seaweed in the B16-F10 murine melanoma cell line. 3G4S did not induce cytotoxicity or proliferation changes; however, it was able to reduce solid tumor growth and metastasis, while not inducing side effects in mice. B16-F10 cells traits related to the metastatic cascade were also impaired by 3G4S, reducing cell invasion, colony-forming capacity and membrane glycoconjugates. Therefore, 3G4S shows promising antitumor activities without the commonly associated drawbacks of cancer treatments and can be further explored.


Subject(s)
Galactans/pharmacology , Green Chemistry Technology , Melanoma, Experimental/prevention & control , Seaweed/chemistry , Sulfates/chemistry , Animals , Apoptosis , Cell Proliferation , Female , Humans , Male , Melanoma, Experimental/secondary , Mice , Mice, Inbred C57BL , Tumor Cells, Cultured
2.
Mar Biotechnol (NY) ; 22(2): 194-206, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31970542

ABSTRACT

Melanoma is a form of skin cancer with high mortality owing to its fast progression and metastatic capacity. The treatments available nowadays are only palliative in advanced stages of the disease. Thus, alternative therapies for cancer treatment are in demand, and molecules from natural sources, such as polysaccharides, could represent new possible therapeutic approaches. Polysaccharides of freshwater and marine algae with biological activities, such as antitumor properties, are greatly reported in the scientific literature. In the present study, a sulfated heterorhamnan obtained from the green seaweed Gayralia brasiliensis (Gb1 fraction) was chemically characterized and its biological activities in the B16-F10 murine melanoma cell line were evaluated. The Gb1 polysaccharidic fraction tested concentrations presented low or absence of cytotoxicity to B16-F10 cells and neither cell proliferation nor cell cycle were altered. Interestingly, Gb1 treatment decreased B16-F10 cells migration and invasion capabilities and CD44 labeling, showing to be a promising compound for further in vitro and in vivo antitumor studies.


Subject(s)
Chlorophyta/chemistry , Deoxy Sugars/pharmacology , Mannans/pharmacology , Melanoma/drug therapy , Animals , Cell Line, Tumor , Cell Movement , Deoxy Sugars/toxicity , Mannans/toxicity , Mice , Neoplasm Invasiveness , Sulfates
3.
Carbohydr Polym ; 178: 95-104, 2017 Dec 15.
Article in English | MEDLINE | ID: mdl-29050620

ABSTRACT

A heteropolysaccharide was isolated by cold aqueous extraction from edible mushroom Pleurotus eryngii ("King Oyster") basidiocarps and its biological properties were evaluated. Structural assignments were carried out using mono- and bidimensional NMR spectroscopy, monosaccharide composition, and methylation analyses. A mannogalactan having a main chain of (1→6)-linked α-d-galactopyranosyl and 3-O-methyl-α-d-galactopyranosyl residues, both partially substituted at OH-2 by ß-d-Manp (MG-Pe) single-unit was found. Biological effects of mannogalactan from P. eryngii (MG-Pe) were tested against murine melanoma cells. MG-Pe was non-cytotoxic, but reduced in vitro melanoma cells invasion. Also, 50mg/kg MG-Pe administration to melanoma-bearing C57BL/6 mice up to 10days decreased in 60% the tumor volume compared to control. Additionally, no changes were observed when biochemical profile, complete blood cells count (CBC), organs, and body weight were analyzed. Mg-Pe was shown to be a promising anti-melanoma molecule capable of switching melanoma cells to a non-invasive phenotype with no toxicity to melanoma-bearing mice.


Subject(s)
Fungal Polysaccharides/pharmacology , Galactans/pharmacology , Melanoma/drug therapy , Pleurotus/chemistry , Animals , Fruiting Bodies, Fungal/chemistry , Magnetic Resonance Spectroscopy , Mice , Mice, Inbred C57BL
4.
Zoonoses Public Health ; 56(6-7): 391-406, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19486321

ABSTRACT

The αGal HyperAcute(®) Technology exploits a robust zoonotic blockade to enhance potency of antiviral vaccines. Naturally acquired immunity against the common αGal epitope [galactose-alpha(1,3)-galactose-beta(1,4)N-acetylglucosamine-R (Gal-α(1,3)-Gal-ß(1,4)-GlcNAc-R)] is facilitated by the loss of a key enzyme in the epitope's biosynthetic pathway. As human cells are devoid of this epitope, chronic stimulus from gut flora leads to high levels of circulating anti-αGal antibodies and the development of a robust immune pathway. As the αGal epitope is immediately recognized as foreign, the naturally acquired αGal immune pathway in humans serves as a strong barrier to zoonotic infection. The αGal HyperAcute(®) Technology takes advantage of this natural process to facilitate the rapid presentation of modified antigens to antigen-presenting cells, leading to a strong immune response. The evolutionary immunity to αGal ensures that the presence of αGal epitopes on antigens will lead to a robust immune response involving cross-activation of T(H)1 immunity, characterized by cytokine secretion and increased phagocytic activity, and T(H)2 immunity characterized by high antibody titres. αGal epitopes can be applied to antiviral vaccines by biological, enzymatic or chemical means. Several detection methods that directly and indirectly verify αGal addition are discussed. Enhanced immunogenicity (humoral and cellular) of αGal-modified vaccines is shown for several antiviral vaccine candidates. αGal modification of antiviral vaccine components leads to enhanced immunogenicity. The existing body of literature describing the utility of αGal epitopes as a safe and robust immunostimulatory and -modulatory agent in humans supports the basis for applying the αGal HyperAcute(®) Technology to the improvement of antiviral vaccines, both new and currently approved.


Subject(s)
Galactosyltransferases/immunology , Galactosyltransferases/metabolism , Viral Vaccines/immunology , Adjuvants, Immunologic , Animals , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/metabolism , Cells, Cultured , Epitopes/metabolism , Humans , Vaccination , Zoonoses
5.
Clin Immunol ; 90(2): 256-65, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10080838

ABSTRACT

In the present study we investigated the role of nitric oxide (NO) in the effector mechanisms of host defense against Cryptococcus neoformans in vivo. Our results showed an increase of NO produced by the peritoneal macrophages from 14-days infected rats compared with normal rats. These cells were capable of killing C. neoformans to a greater extent than macrophages from noninfected rats (80% vs 20%, respectively). The killing of C. neoformans by infected cells was efficiently inhibited (80% to 35%, P < 0.001) by adding aminoguanidine (AG) to the cultures. We observed that in vivo administration of AG to the infected animals efficiently inhibited the metabolism producing NO and failed to affect that of normal animals. When the NO synthase (NOS) was inhibited in vivo in the infected animals, a marked increase of the fungi charge in the organs was observed with respect to the normal animals treated with AG. We also observed that the course of the infection is drastically modified after the inhibition of NO production because all the animals infected and treated with AG died from cryptococcosis before 20 days postinfection (p.i.). These results indicate that NO is a crucial molecule in the effector mechanisms in this infection model.


Subject(s)
Cryptococcosis/immunology , Cryptococcus neoformans/immunology , Nitric Oxide/immunology , Animals , Cryptococcosis/metabolism , Cryptococcosis/pathology , Disease Models, Animal , Enzyme Inhibitors/pharmacology , Female , Guanidines/pharmacology , In Vitro Techniques , Lung/immunology , Lung/pathology , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/metabolism , Nitric Oxide/biosynthesis , Nitric Oxide Synthase/antagonists & inhibitors , Rats , Rats, Wistar
6.
Clin Immunol Immunopathol ; 86(1): 16-26, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9434793

ABSTRACT

We investigated the proliferative response to mitogens of spleen mononuclear (Spm) cells from Cryptococcus neoformans-infected rats. We determined reactive oxygen intermediates (ROI) and nitric oxide (NO) production by peritoneal and Spm cells, and evaluated the correlation of the proliferative response with NO and ROI production. The proliferative response of Spm cells from infected rats dramatically decreased at 14 and 21 days postinfection (PI). The unresponsiveness of Spm cells from 14-day infected rats was not abrogated by the addition of L-NAME and AG, indicating that NO is not involved in the antiproliferative response of experimental cells. When SOD, catalase, and indomethacin were added to the cultures, the suppression was still observed, indicating that ROI and prostaglandins are not involved in the unresponsiveness of lymphocytes. The proliferative response of lymphocytes from 14-day infected rats was significantly improved when cultures were made in the presence of Con A and exogenous IL-2. Additionally, a purified T-rich fraction from infected rats cultured with control macrophages recovered the normal proliferative response. This result indicates that macrophages from infected rats mediate the unresponsiveness of lymphocytes, probably by reducing the ability of lymphocytes to secrete IL-2.


Subject(s)
Cryptococcosis/metabolism , Lymphocyte Activation/physiology , Lymphocyte Subsets/immunology , Macrophages, Peritoneal/physiology , Nitric Oxide/physiology , Spleen/cytology , Animals , Antioxidants/pharmacology , Catalase/pharmacology , Concanavalin A/pharmacology , Enzyme Inhibitors/pharmacology , Female , Guanidines/pharmacology , Indomethacin/pharmacology , Interleukin-2/metabolism , Interleukin-2/pharmacology , Lipopolysaccharides/pharmacology , Lymphocyte Subsets/cytology , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Prostaglandin Antagonists/pharmacology , Rats , Rats, Wistar , Recombinant Proteins/pharmacology , Secretory Rate/drug effects , Superoxide Dismutase/pharmacology
7.
J Med Vet Mycol ; 32(6): 405-14, 1994 Dec.
Article in English | MEDLINE | ID: mdl-7738723

ABSTRACT

The biochemical basis of peritoneal cell cytotoxicity for Cryptococcus neoformans was studied by measuring the killing of the yeast by peritoneal resident cells and peritoneal exudate cells obtained from normal and proteose-peptone-injected animals, respectively. Both cell populations killed C. neoformans to an equivalent extent after 3 h incubation. Exudate cells showed anti-cryptococcal activity from the first hour of incubation, while no killing was observed with resident cells before 3 h. Both cell populations triggered a respiratory burst in response to opsonized C. neoformans as indicated by the fact that killing of the yeast was inhibited by scavengers of reactive oxygen intermediates (ROI). C. neoformans susceptibility to H2O2 and hydroxyl radicals in cell-free systems is demonstrated by incubating a yeast suspension with different concentrations of H2O2 and Fenton's reagents, respectively. These results suggest that oxygen metabolites play an active role in C. neoformans killing.


Subject(s)
Cryptococcus neoformans/physiology , Peritoneum/cytology , Animals , Cells, Cultured , Female , Ferrous Compounds/pharmacology , Hydrogen Peroxide/pharmacology , Male , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Respiratory Burst/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...